vs
Side-by-side financial comparison of LISATA THERAPEUTICS, INC. (LSTA) and Netcapital Inc. (NCPL). Click either name above to swap in a different company.
LISATA THERAPEUTICS, INC. is the larger business by last-quarter revenue ($100.0K vs $94.3K, roughly 1.1× Netcapital Inc.). On growth, Netcapital Inc. posted the faster year-over-year revenue change (-38.2% vs -90.0%).
Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022.
Netcapital Inc. runs a U.S.-focused digital private capital markets platform that connects growth-seeking early startups, small and medium private businesses with accredited and non-accredited individual investors, providing fundraising support for issuers and accessible alternative investment options for platform users.
LSTA vs NCPL — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $100.0K | $94.3K |
| Net Profit | — | $-1.8M |
| Gross Margin | — | 98.1% |
| Operating Margin | — | -2304.6% |
| Net Margin | — | -1921.5% |
| Revenue YoY | -90.0% | -38.2% |
| Net Profit YoY | 35.9% | 39.7% |
| EPS (diluted) | — | $-0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $94.3K | ||
| Q4 25 | $100.0K | $51.1K | ||
| Q3 25 | $0 | $190.1K | ||
| Q2 25 | $70.0K | $404.0K | ||
| Q1 25 | $0 | $152.7K | ||
| Q4 24 | — | $170.5K | ||
| Q3 24 | $0 | $142.2K | ||
| Q2 24 | $0 | $347.2K |
| Q1 26 | — | $-1.8M | ||
| Q4 25 | — | $-2.1M | ||
| Q3 25 | $-4.2M | $-3.6M | ||
| Q2 25 | $-4.7M | $-20.5M | ||
| Q1 25 | $-4.7M | $-3.0M | ||
| Q4 24 | — | $-2.2M | ||
| Q3 24 | $-4.9M | $-2.5M | ||
| Q2 24 | $-5.0M | — |
| Q1 26 | — | 98.1% | ||
| Q4 25 | — | 96.3% | ||
| Q3 25 | — | 96.1% | ||
| Q2 25 | — | 99.2% | ||
| Q1 25 | — | 95.3% | ||
| Q4 24 | — | 88.4% | ||
| Q3 24 | — | 92.8% | ||
| Q2 24 | — | 96.8% |
| Q1 26 | — | -2304.6% | ||
| Q4 25 | — | -4149.6% | ||
| Q3 25 | — | -1728.8% | ||
| Q2 25 | -6954.3% | -476.0% | ||
| Q1 25 | — | -1105.4% | ||
| Q4 24 | — | -1291.5% | ||
| Q3 24 | — | -1763.5% | ||
| Q2 24 | — | — |
| Q1 26 | — | -1921.5% | ||
| Q4 25 | — | -4169.3% | ||
| Q3 25 | — | -1916.3% | ||
| Q2 25 | -6655.7% | -5085.6% | ||
| Q1 25 | — | -1969.1% | ||
| Q4 24 | — | -1302.1% | ||
| Q3 24 | — | -1776.9% | ||
| Q2 24 | — | — |
| Q1 26 | — | $-0.32 | ||
| Q4 25 | — | $-0.44 | ||
| Q3 25 | $-0.49 | $-1.27 | ||
| Q2 25 | $-0.54 | $-11.38 | ||
| Q1 25 | $-0.55 | $-1.57 | ||
| Q4 24 | — | $-2.34 | ||
| Q3 24 | $-0.59 | $-5.10 | ||
| Q2 24 | $-0.61 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $16.0M | — |
| Total DebtLower is stronger | — | $492.4K |
| Stockholders' EquityBook value | $14.9M | $21.6M |
| Total Assets | $17.7M | $26.1M |
| Debt / EquityLower = less leverage | — | 0.02× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $16.0M | — | ||
| Q3 25 | $19.0M | — | ||
| Q2 25 | $16.8M | — | ||
| Q1 25 | $20.2M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $19.5M | — | ||
| Q2 24 | $28.3M | — |
| Q1 26 | — | $492.4K | ||
| Q4 25 | — | $495.8K | ||
| Q3 25 | — | $500.0K | ||
| Q2 25 | — | $500.0K | ||
| Q1 25 | — | $500.0K | ||
| Q4 24 | — | $500.0K | ||
| Q3 24 | — | $500.0K | ||
| Q2 24 | — | $500.0K |
| Q1 26 | — | $21.6M | ||
| Q4 25 | $14.9M | $21.4M | ||
| Q3 25 | $17.4M | $23.1M | ||
| Q2 25 | $21.0M | $14.9M | ||
| Q1 25 | $25.4M | $35.0M | ||
| Q4 24 | — | $37.4M | ||
| Q3 24 | $33.7M | $37.5M | ||
| Q2 24 | $38.2M | $37.9M |
| Q1 26 | — | $26.1M | ||
| Q4 25 | $17.7M | $25.4M | ||
| Q3 25 | $21.8M | $28.4M | ||
| Q2 25 | $25.2M | $20.9M | ||
| Q1 25 | $29.0M | $39.9M | ||
| Q4 24 | — | $41.9M | ||
| Q3 24 | $38.2M | $41.4M | ||
| Q2 24 | $42.6M | $41.6M |
| Q1 26 | — | 0.02× | ||
| Q4 25 | — | 0.02× | ||
| Q3 25 | — | 0.02× | ||
| Q2 25 | — | 0.03× | ||
| Q1 25 | — | 0.01× | ||
| Q4 24 | — | 0.01× | ||
| Q3 24 | — | 0.01× | ||
| Q2 24 | — | 0.01× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.9M | $-868.7K |
| Free Cash FlowOCF − Capex | $-16.0M | — |
| FCF MarginFCF / Revenue | -15977.0% | — |
| Capex IntensityCapex / Revenue | 28.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $-868.7K | ||
| Q4 25 | $-15.9M | $-2.6M | ||
| Q3 25 | $-3.3M | $-4.2M | ||
| Q2 25 | $-4.0M | $-5.3M | ||
| Q1 25 | $-5.4M | $-1.2M | ||
| Q4 24 | — | $-1.5M | ||
| Q3 24 | $-2.5M | $-2.0M | ||
| Q2 24 | $-5.3M | $-4.9M |
| Q1 26 | — | — | ||
| Q4 25 | $-16.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $-5.4M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | -15977.0% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | 28.0% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
